Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: CytoTools AG:  Außerordentliche Hauptversammlung der CytoTools AG vom 18.11.21 stimmt mit 88% für Kapitalerhöhung - klarer Fokus auf die Finanzierung der internationalen Zulassung von DermaPro(R)
DGAP-News: CytoTools AG: Außerordentliche Hauptversammlung der CytoTools AG vom 18.11.21 stimmt mit 88% für Kapitalerhöhung - klarer Fokus auf die Finanzierung der internationalen Zulassung von DermaPro(R)
DGAP-News: CytoTools AG: Außerordentliche Hauptversammlung der CytoTools AG vom 18.11.21 stimmt mit 88% für Kapitalerhöhung - klarer Fokus auf die Finanzierung der internationalen Zulassung von DermaPro(R)
DGAP-News: Burcon nimmt an bevorstehenden Investorenkonferenzen teil
DGAP-News: Burcon nimmt an bevorstehenden Investorenkonferenzen teil
DGAP-News: Burcon nimmt an bevorstehenden Investorenkonferenzen teil
DGAP-News: Burcon to Participate in Upcoming Investor Conferences
DGAP-News: Burcon to Participate in Upcoming Investor Conferences
DGAP-News: Burcon to Participate in Upcoming Investor Conferences
Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
Advanced Auto Parts Stock May be Cheap for a Reason: https://www.marketbeat.com/logos/articles/med_20240826073705_advanced-auto-parts-stock-may-be-cheap-for-a-reaso.jpg
Advanced Auto Parts Stock May be Cheap for a Reason

Advanced Auto Parts Inc. (NYSE: AAP) stock fell 3.8% on August 23, the day after the company reported significantly lower profits than analysts expected in the company's second quarter 2024

Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment: https://www.marketbeat.com/logos/articles/med_20240823074150_cathie-wood-has-90-million-in-this-ai-precision-me.jpg
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment

In just ten days, shares of the mid-cap healthcare stock Tempus AI (NASDAQ: TEM) have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to

Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally: https://www.marketbeat.com/logos/articles/med_20240822125851_diabetes-and-neuro-products-ignite-medtronics-q1-e.jpg
Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally

Shares of medical device manufacturer Medtronic PLC (NYSE: MDT) are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal

Value Investing: Unearthing 3 Hidden Gems in Today's Market: https://www.marketbeat.com/logos/articles/med_20240820115034_value-investing-unearthing-hidden-gems-in-todays-m.jpg
Value Investing: Unearthing 3 Hidden Gems in Today's Market

During times of market volatility and concerns about overvaluation, investors are increasingly turning to time-tested strategies to navigate the complexities of the stock market. Among these

The First Half of 2025 Will Be a Massive Test for AST SpaceMobile: https://www.marketbeat.com/logos/articles/med_20240820113636_the-first-half-of-2025-will-be-a-massive-test-for.jpg
The First Half of 2025 Will Be a Massive Test for AST SpaceMobile

AST SpaceMobile (NASDAQ:ASTS) is in the communication services sector and has seen its shares explode in 2024. The company’s stock is up over 500% this year despite producing little to no

Merck's Stock Dip Offers a Buying Opportunity: Here’s Why: https://www.marketbeat.com/logos/articles/med_20240819101736_chartb-mrk.jpg
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why

Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, but the lowered full-year EPS 2024

This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?: https://www.marketbeat.com/logos/articles/med_20240816144216_this-early-stage-biotech-stock-is-up-400-should-yo.jpg
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?

Avidity Biosciences (NASDAQ: RNA) is a biopharmaceutical stock focusing on RNA therapeutics. The company’s stock is up around 400% so far in 2024.

However, even with this massive appreciation

3 Stocks to Buy for a Soft Landing, If There Is One: https://www.marketbeat.com/logos/articles/med_20240815092649_3-stocks-to-buy-for-a-soft-landing-if-there-is-one.jpg
3 Stocks to Buy for a Soft Landing, If There Is One

Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve’s monetary policy regarding interest rates is neither too restrictive nor too

Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs: https://www.marketbeat.com/logos/articles/med_20240814092658_defying-the-market-3-mega-cap-stocks-soaring-to-ne.jpg
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs

In a market characterized by uncertainty and volatility, it's increasingly rare to find stocks that are weathering the storm and thriving. Yet, a select few from various sectors are doing just

MedMira startet Klinische Tests mit Multiplo® Complete Syphilis (TP/nTP) Antibody Test - ein möglicher Game Changer um die Syphilis-Gesundheitskrise in Kanada zu meistern: https://www.irw-press.at/prcom/images/messages/2024/76536/MedMira_14082024_DEPRcom.001.png
MedMira startet Klinische Tests mit Multiplo® Complete Syphilis (TP/nTP) Antibody Test - ein möglicher Game Changer um die Syphilis-Gesundheitskrise in Kanada zu meistern

Halifax, Nova Scotia, 13. August 2024 - MedMira Inc. (MedMira) (TSXV: MIR) gibt mit Freude bekannt, dass es vollständige klinische Studien für seinen einzigartigen Multiplo® Complete

Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada: https://www.irw-press.at/prcom/images/messages/2024/76536/MedMira_14082024_ENPRcom.001.png
Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada

Halifax, Nova Scotia, 13 August, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody

Der Modern Data Quality Summit 2024 von DQLabs ebnet den Weg zu KI-Bereitschaft: https://www.irw-press.at/prcom/images/messages/2024/76530/DQLabs_081324_DEPRcom.001.jpeg
Der Modern Data Quality Summit 2024 von DQLabs ebnet den Weg zu KI-Bereitschaft

Hochwertige Daten, intelligente KI - Sie sind so bereit für KI wie Ihre Daten

 

PASADENA, KALIFORNIEN / ACCESSWIRE / 13. August 2024 / DQLabs, das Unternehmen für moderne Data Quality und

DQLabs Modern Data Quality Summit 2024 Accelerates Path to AI-Readiness: https://www.irw-press.at/prcom/images/messages/2024/76530/DQLabs_081324_ENPRcom.001.jpeg
DQLabs Modern Data Quality Summit 2024 Accelerates Path to AI-Readiness

Quality Data, Smart AI - You are as AI-Ready as Your Data

 

PASADENA, CA / ACCESSWIRE / August 13, 2024 / DQLabs, the Modern Data Quality and Observability company is hosting the Modern Data

Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?: https://www.marketbeat.com/logos/articles/med_20240811162653_chartx-nvax.jpg
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?

Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Its most significant vaccine, Nuvaxovid, is for COVI

MicroVision meldet die Ergebnisse des zweiten Quartals 2024: https://www.irw-press.at/prcom/images/messages/2024/76468/MicroVisionNR08072024_DE_PRcom.003.png
MicroVision meldet die Ergebnisse des zweiten Quartals 2024

REDMOND, WA / ACCESSWIRE / 7. August 2024 / MicroVision, Inc. (NASDAQ:MVIS), ein führender Anbieter von MEMS-basierten Festkörper-Automobil-LiDAR- und modernen Fahrerassistenzlösungen (ADAS),

MicroVision Announces Second Quarter 2024 Results: https://www.irw-press.at/prcom/images/messages/2024/76468/MicroVisionNR08072024_PRcom.003.png
MicroVision Announces Second Quarter 2024 Results

REDMOND, WA / ACCESSWIRE / August 7, 2024 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its second quarter 2024

Amgen's MariTide Weight Loss Potential: Stock Outlook: https://www.marketbeat.com/logos/articles/med_20240807084756_amgens-maritide-weight-loss-potential-stock-outloo.png
Amgen's MariTide Weight Loss Potential: Stock Outlook

Amgen (NASDAQ: AMGN) is a biotechnology firm that has made its way into the weight loss treatment battle. The company’s shares have performed relatively well in 2024, providing a total return of

Why AST SpaceMobile Stock is a Must-Watch in 2024: https://www.marketbeat.com/logos/articles/med_20240806145404_ast-spacemobile-nears-launch-of-direct-to-satellit.jpg
Why AST SpaceMobile Stock is a Must-Watch in 2024

AST SpaceMobile Inc. (NASDAQ: ASTS) is a little-known satellite company with ambitious plans to create the world's first and only space-based cellular broadband network. The goal is to enable

Medical Technology Stock Benefits from Rising Acute Care Demand: https://www.marketbeat.com/logos/articles/med_20240804190513_chartg-syk.jpg
Medical Technology Stock Benefits from Rising Acute Care Demand

Medical and surgical products manufacturer Stryker Co. (NYSE: SYK) is a beneficiary of the acute care boom occurring in the healthcare industry. Acute care is considered short-term intensive

Humana Slides on Profitability Concerns Despite Q2 Earnings Beat: https://www.marketbeat.com/logos/articles/med_20240801073139_humana-slides-on-profitability-concerns-despite-q2.jpg
Humana Slides on Profitability Concerns Despite Q2 Earnings Beat

Humana Inc. (NYSE: HUM) is a leading health insurer predominantly focused on Medicare Advantage plans, serving millions of individuals and families nationwide. The company's business model centers

AbbVie Analysts Lead the Stock Higher as Humira Worries Recede: https://www.marketbeat.com/logos/articles/med_20240730104221_chart-abbv-7303034.png
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede

AbbVie (NYSE: ABBV) was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader